Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Blueprint Genetics | RCV001074953 | SCV001240560 | likely pathogenic | Retinal dystrophy | 2017-08-23 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001862587 | SCV002229971 | pathogenic | not provided | 2021-07-01 | criteria provided, single submitter | clinical testing | This variant is also known as IVS29+1G>C. For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 866716). Disruption of this splice site has been observed in individuals with Usher syndrome and inherited retinal dystrophy (PMID: 18641288; Invitae). This variant is not present in population databases (ExAC no frequency). This sequence change affects a donor splice site in intron 29 of the USH2A gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). |
Genome- |
RCV003446612 | SCV004172114 | likely pathogenic | Retinitis pigmentosa 39 | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003446612 | SCV004208222 | pathogenic | Retinitis pigmentosa 39 | 2023-10-02 | criteria provided, single submitter | clinical testing |